At Extreme Investor Network, we are always on the lookout for the latest business news that can impact investors and consumers alike. Today, we want to discuss Walgreens’ recent announcement regarding the launch of its own cheaper version of the over-the-counter opioid overdose reversal spray naloxone.
Naloxone is a life-saving medication that can temporarily reverse the effects of an opioid overdose, including heroin and fentanyl. With the opioid epidemic continuing to devastate communities across the United States, Walgreens aims to increase access to this vital medication by offering a more affordable option.
The company will be selling a two-dose pack of “Walgreens Brand Naloxone” for $34.99, which is approximately $10 cheaper than the branded drug Narcan. This move is part of Walgreens’ commitment to making naloxone more accessible to those who need it most.
Dr. Priya Mammen, senior medical director in Walgreens’ Office of Clinical Integrity, emphasized the importance of increasing accessibility to naloxone. In a recent interview with CNBC, she stated, “It’s a life-saving medication that can intervene on anyone at any age, anytime, and it’s something that families, individuals, and communities can empower themselves by having it available and can be part of the solution.”
With the FDA’s recent approval of Walgreens’ prescription-free naloxone nasal spray, the company hopes to reduce the stigma associated with drug overdoses and naloxone use. By offering a more affordable option, Walgreens is taking a crucial step towards combating the opioid epidemic and saving lives.
Stay tuned to Extreme Investor Network for more updates on the latest business news and trends that can impact your investment decisions. Together, we can navigate the ever-changing landscape of the business world and make informed choices that drive success.